lilly retatrutide trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II Lilly's triple agonist achieves 16.8%
Description
doi: 10.1016/j.ejphar.2019.172715
Gastrointestinal symptoms (nausea, vomiting, diarrhoea) are most common, typically improving with gradual dose titration
comparators had no GLP-1 prescriptions
Metabolic Assessment & GLP1 Fit Check GLP1 Metabolic Reset (first 90 days) Baseline labs, start your personalized dose, hydration, and protein targets
Additionally, rapid weight loss associated with these medications might sometimes precipitate headaches through various metabolic changes, though this mechanism requires further study
